{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009922","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.742483+00:00","generated_at":"2026-05-24T22:38:51.746285+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Shuttle Pharma appoints Christopher Cooper as interim Co-CEO to boost business activities","bullets":["Christopher Cooper appointed interim Co-CEO effective March 11, 2025; focused on capital markets and business capabilities.","Dr. Anatoly Dritschilo continues as Chairman and Co-CEO overseeing scientific and clinical trial activities.","Consulting agreement with Cooper's entity pays $20,000/month for six months, 40 hours/week, with 30-day termination notice.","Cooper has 27 years of management/finance experience, raised over $100M in debt and equity for prior clients.","Company's ongoing Phase 2 trial of Ropidoxuridine for glioblastoma continues under Dritschilo's leadership."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009922","json":"https://secwatch.observer/filing/0001493152-25-009922.json","markdown":"https://secwatch.observer/filing/0001493152-25-009922.md","text":"https://secwatch.observer/filing/0001493152-25-009922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:38:51.746285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7795a7f75e","claim":"Christopher Cooper was appointed as interim co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..","evidence_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001628280-26-039461","ticker":"GRAL","company_name":"GRAIL, Inc.","filed_at":"2026-06-01T20:07:27+00:00","headline":"GRAIL appoints Joshua Ofman as CEO with amended compensation and severance","event_type":"leadership","sec_items":["5.02","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 8.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039461","json":"https://secwatch.observer/filing/0001628280-26-039461.json","markdown":"https://secwatch.observer/filing/0001628280-26-039461.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/0001628280-26-039461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/gral-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","comparable_excerpt":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the Company’s board of directors (the “Board”) approved an amended and restated offer letter (the “Amended Offer Letter”) and authorized and directed the Company to enter into such Amended Offer Letter with Dr. Ofman, with the Amended Offer Letter effective as of June 1, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/0001628280-26-039461-index.htm"}},{"accession":"0001515156-26-000069","ticker":"ARQ","company_name":"Arq, Inc.","filed_at":"2026-05-27T20:32:10+00:00","headline":"Arq appoints Shimon Steinmetz as CFO, CAO Stacia Hansen resigns","event_type":"leadership","sec_items":["5.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 8.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001515156-26-000069","json":"https://secwatch.observer/filing/0001515156-26-000069.json","markdown":"https://secwatch.observer/filing/0001515156-26-000069.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515156/000151515626000069/0001515156-26-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515156/000151515626000069/ades-20260520.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","comparable_excerpt":"On May 20, 2026, Stacia Hansen, the Chief Accounting Officer and Treasurer of the Company, submitted her resignation and the Board accepted such resignation. The effective date of Ms. Hansen's resignation as Chief Accounting Officer is expected to be June 12, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1515156/000151515626000069/0001515156-26-000069-index.htm"}},{"accession":"0001193125-26-251709","ticker":"CRVL","company_name":"CORVEL CORP","filed_at":"2026-06-01T21:05:42+00:00","headline":"CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251709","json":"https://secwatch.observer/filing/0001193125-26-251709.json","markdown":"https://secwatch.observer/filing/0001193125-26-251709.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/d24231d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","comparable_excerpt":"In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm"}},{"accession":"0001140361-26-023584","ticker":"WTTR","company_name":"Select Water Solutions, Inc.","filed_at":"2026-06-01T21:00:50+00:00","headline":"Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023584","json":"https://secwatch.observer/filing/0001140361-26-023584.json","markdown":"https://secwatch.observer/filing/0001140361-26-023584.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/ef20075332_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","comparable_excerpt":"Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm"}},{"accession":"0001671933-26-000063","ticker":"TTD","company_name":"Trade Desk, Inc.","filed_at":"2026-06-01T20:35:28+00:00","headline":"The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001671933-26-000063","json":"https://secwatch.observer/filing/0001671933-26-000063.json","markdown":"https://secwatch.observer/filing/0001671933-26-000063.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/ttd-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","comparable_excerpt":"On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm"}},{"accession":"0000105770-26-000080","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","headline":"West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000080","json":"https://secwatch.observer/filing/0000105770-26-000080.json","markdown":"https://secwatch.observer/filing/0000105770-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/wst-20260531.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","comparable_excerpt":"As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"}},{"accession":"0000060519-26-000024","ticker":"LPX","company_name":"LOUISIANA-PACIFIC CORP","filed_at":"2026-06-01T20:31:12+00:00","headline":"LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000060519-26-000024","json":"https://secwatch.observer/filing/0000060519-26-000024.json","markdown":"https://secwatch.observer/filing/0000060519-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/lpx-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","comparable_excerpt":"On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm"}},{"accession":"0001193125-26-251467","ticker":"PENG","company_name":"Penguin Solutions, Inc.","filed_at":"2026-06-01T20:17:28+00:00","headline":"Penguin Solutions CFO Nate Olmstead to step down; Aaron Johnson named interim CFO; reaffirms FY2026 guidance at high end","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251467","json":"https://secwatch.observer/filing/0001193125-26-251467.json","markdown":"https://secwatch.observer/filing/0001193125-26-251467.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/d104493d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm","comparable_excerpt":"On May 31, 2026, the board of directors of the Company appointed Aaron Johnson, the Company’s Vice President, Finance and Accounting, as interim CFO and as the Company’s principal financial and accounting officer, succeeding Mr. Olmstead in these positions effective as of July 9, 2026, on an interim basis until the Company appoints a successor.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}